Clinical Trials Logo
  1. Home
  2. Anti-Infective Agents
  3. NCT01073553

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules

Anti-Infective Agents Clinical Trial

Official title:
Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef (Cephalexin 500 mg Capsules) From Bayer and Keflex (Cephalexin 250 mg Capsules) From Eli Lilly po in Healthy Subjects Using Equivalent Concentrations

Clinical Trial Summary

A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01073553
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date October 2009
Completion date October 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT03279120 - Safety, PK, and PD Study of IVRs Releasing TFV and LNG Phase 1
Not yet recruiting NCT03793946 - A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant N/A
Completed NCT01073540 - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension Phase 1
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Completed NCT01231763 - Acceptability Study of Vaginal Films for HIV Prevention N/A
Completed NCT01244698 - Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Phase 4
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT01690533 - Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
Completed NCT01105208 - Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension Phase 1
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Completed NCT02046512 - Probiotics to Promote Intestinal Health Phase 4
Completed NCT04210713 - Neuroimmune Dysfunction in Alcohol Use Disorder Phase 1
Completed NCT04448665 - Compliance of Initial Empiric Antimicrobial Therapy
Completed NCT05979207 - Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Phase 1
Recruiting NCT02242968 - Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products